who medicines strategy - libdoc.who.int - World Health Organization
who medicines strategy - libdoc.who.int - World Health Organization who medicines strategy - libdoc.who.int - World Health Organization
WHO MEDICINES STRATEGY 2004-2007 | 118EO 7.3Independent and reliablemedicines information identified,disseminated, and promotedRationaleProgressReliable, objective, and evidence-basedThe major advance in this area has been theinformation is the foundation of rationalproduction of the WHO Model Formulary andmedicines use. With the development ofthe WHO Medicines Library (see also EO 7.2). Inspecialized networks and websites, access to such addition, a manual on the production of Nationalinformation is readily available in most parts of or Institutional Formularies based on the WHOthe world where there is access to the Internet. Model Formulary will be released in 2004.However, this still leaves many countries without This manual will be issued as a CD-ROM, alsoaccess to independent and reliable medicinescontaining the WHO Model Formulary.information. In a global survey carried out in1999, only 50% of 138 reporting countries hadDrug Information Centres. The regional rangewas 40%-89%. The lack of independent andreliable medicines information in many countriesis compounded by the pharmaceutical industry’sinvestment in marketing activities, includingdirect-to-consumer advertising. In the USA, forexample, the pharmaceutical industry spentabout US$ 15 billion on promotional activities in2000. 61
COMPONENTS OF THE STRATEGY | 119Challenges remainingInformation available to professionals andconsumers is frequently provided by themanufacturers or suppliers of medicines, bothof which have a commercial interest, ratherthan from independent sources with a consumerinterest. The imbalance in funding for suchactivities means that it is difficult for prescribers toobtain comparative unbiased information.Meeting the challenges 2004-2007Over the next four years WHO will:> provide technical support to strengthennational capacity to develop and disseminatemedicines information.> support national efforts to produce nationalor institutional formularies and national druginformation bulletins.> work with the International Society of DrugBulletins to produce a manual for use atnational level in the production of DrugInformation Bulletins.OUTCOME INDICATORS1999 2003 2007No. of countries with a national medicines informationcentre able to provide independent information onmedicines to prescribers and/or dispensersNo. of countries with a medicines information centre /service accessible to consumers#REPORTING % TARGET#REPORTING % TARGET62/123 50% 59% 53/129 41% 50%na na na 45/127 35% 40%
- Page 80 and 81: WHO MEDICINES STRATEGY 2004-2007 |
- Page 82 and 83: WHO MEDICINES STRATEGY 2004-2007 |
- Page 84 and 85: WHO MEDICINES STRATEGY 2004-2007 |
- Page 86 and 87: WHO MEDICINES STRATEGY 2004-2007 |
- Page 88 and 89: WHO MEDICINES STRATEGY 2004-2007 |
- Page 90 and 91: WHO MEDICINES STRATEGY 2004-2007 |
- Page 92 and 93: WHO MEDICINES STRATEGY 2004-2007 |
- Page 94 and 95: WHO MEDICINES STRATEGY 2004-2007 |
- Page 96 and 97: WHO MEDICINES STRATEGY 2004-2007 |
- Page 98 and 99: WHO MEDICINES STRATEGY 2004-2007 |
- Page 100 and 101: WHO MEDICINES STRATEGY 2004-2007 |
- Page 102 and 103: WHO MEDICINES STRATEGY 2004-2007 |
- Page 104 and 105: WHO MEDICINES STRATEGY 2004-2007 |
- Page 106 and 107: WHO MEDICINES STRATEGY 2004-2007 |
- Page 108 and 109: WHO MEDICINES STRATEGY 2004-2007 |
- Page 110 and 111: WHO MEDICINES STRATEGY 2004-2007 |
- Page 112 and 113: WHO MEDICINES STRATEGY 2004-2007 |
- Page 114 and 115: WHO MEDICINES STRATEGY 2004-2007 |
- Page 116 and 117: WHO MEDICINES STRATEGY 2004-2007 |
- Page 118 and 119: WHO MEDICINES STRATEGY 2004-2007 |
- Page 120 and 121: WHO MEDICINES STRATEGY 2004-2007 |
- Page 122 and 123: WHO MEDICINES STRATEGY 2004-2007 |
- Page 124 and 125: WHO MEDICINES STRATEGY 2004-2007 |
- Page 126 and 127: WHO MEDICINES STRATEGY 2004-2007 |
- Page 128 and 129: WHO MEDICINES STRATEGY 2004-2007 |
- Page 132 and 133: WHO MEDICINES STRATEGY 2004-2007 |
- Page 134 and 135: WHO MEDICINES STRATEGY 2004-2007 |
- Page 136 and 137: WHO MEDICINES STRATEGY 2004-2007 |
- Page 138 and 139: WHO MEDICINES STRATEGY 2004-2007 |
- Page 140 and 141: WHO MEDICINES STRATEGY 2004-2007 |
- Page 142 and 143: WHO MEDICINES STRATEGY 2004-2007 |
- Page 144 and 145: WHO MEDICINES STRATEGY 2004-2007 |
- Page 146 and 147: WHO MEDICINES STRATEGY 2004-2007 |
- Page 148 and 149: WHO MEDICINES STRATEGY 2004-2007 |
- Page 150 and 151: WHO MEDICINES STRATEGY 2004-2007 |
- Page 152 and 153: WHO MEDICINES STRATEGY 2004-2007 |
- Page 154 and 155: WHO MEDICINES STRATEGY 2004-2007 |
- Page 157 and 158: REFERENCES
- Page 159 and 160: REFERENCES | 1471Annual report 2000
- Page 161 and 162: REFERENCES | 14912 th Model List of
WHO MEDICINES STRATEGY 2004-2007 | 118EO 7.3Independent and reliable<strong>medicines</strong> information identified,disseminated, and promotedRationaleProgressReliable, objective, and evidence-basedThe major advance in this area has been theinformation is the foundation of rationalproduction of the WHO Model Formulary and<strong>medicines</strong> use. With the development ofthe WHO Medicines Library (see also EO 7.2). Inspecialized networks and websites, access to such addition, a manual on the production of Nationalinformation is readily available in most parts of or Institutional Formularies based on the WHOthe world where there is access to the Internet. Model Formulary will be released in 2004.However, this still leaves many countries without This manual will be issued as a CD-ROM, alsoaccess to independent and reliable <strong>medicines</strong>containing the WHO Model Formulary.information. In a global survey carried out in1999, only 50% of 138 reporting countries hadDrug Information Centres. The regional rangewas 40%-89%. The lack of independent andreliable <strong>medicines</strong> information in many countriesis compounded by the pharmaceutical industry’sinvestment in marketing activities, includingdirect-to-consumer advertising. In the USA, forexample, the pharmaceutical industry spentabout US$ 15 billion on promotional activities in2000. 61